Stockscreener 앱 받기
7.58
2.19%
-0.17
시간 외 거래:
7.58
전일 마감가:
$7.75
열려 있는:
$7.7
하루 거래량:
1.01M
Relative Volume:
0.89
시가총액:
$1.23B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-5.6148
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
+0.93%
1개월 성능:
+9.22%
6개월 성능:
-12.67%
1년 성능:
-16.70%
1일 변동 폭
$7.53
$7.82
1주일 범위
$7.28
$8.04
52주 변동 폭
$4.06
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.58 | 1.23B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - Simply Wall St
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq
Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com
RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
Ocular rises as Needham issues new Buy on lead candidate - MSN
When (OCUL) Moves Investors should Listen - Stock Traders Daily
Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus.com
Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target -March 11, 2025 at 07:30 am EDT - Marketscreener.com
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Ocular Therapeutix initiated with a Buy at Needham - TipRanks
Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World
Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World
Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire
Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN
Truist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Traders Purchase High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus.com
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness - TipRanks
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
New York State Common Retirement Fund Boosts Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback - MSN
Ocular Therapeutix Reports Fourth Quarter and Full Year 2024 Revenue Growth - Vision Monday
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings - Defense World
Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions - TipRanks
Ocular Therapeutix Reports 2024 Financial Results and Progress - TipRanks
Ocular Therapeutix Earnings Call Highlights Progress and Challenges - TipRanks
Ocular Therapeutix: Q4 Earnings Snapshot - CTPost
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast - Investing.com India
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast By Investing.com - Investing.com Australia
BofA cuts Ocular Therapeutix target to $17, maintains buy By Investing.com - Investing.com UK
Ocular Therapeutix shares tumble on earnings miss By Investing.com - Investing.com South Africa
Ocular Therapeutix shares tumble on earnings miss - Investing.com
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - MSN
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):